Javier Rodriguez - 14 Mar 2023 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Chief Legal Officer, Senior Vice President and Corporate Secretary
Signature
/s/ Javier Rodriguez
Issuer symbol
BTAI
Transactions as of
14 Mar 2023
Net transactions value
-$18,644
Form type
4
Filing time
16 Mar 2023, 17:58:08 UTC
Previous filing
17 May 2022
Next filing
16 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTAI Common Stock Options Exercise +2,084 2,084 14 Mar 2023 Direct F1
transaction BTAI Common Stock Sale $18,644 -950 -46% $19.62 1,135 15 Mar 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Restricted Stock Units Options Exercise $0 -2,084 -25% $0.000000 6,253 14 Mar 2023 Common Stock 2,084 Direct F1, F3
transaction BTAI Restricted Stock Units Award $0 +9,000 $0.000000 9,000 15 Mar 2023 Common Stock 9,000 Direct F1, F4
transaction BTAI Stock Option (Right to Buy) Award $0 +32,000 $0.000000 32,000 15 Mar 2023 Common Stock 32,000 $19.60 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2022.
F3 On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F4 The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F5 The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 15, 2023 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

Remarks:

Chief Legal Officer, Senior Vice President and Corporate Secretary